Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

Axsome Therapeutics shares reached a new 52-week high price today after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application fil...
Streetwise Reports | December 17, 2019 |

Clinical Program Started for Agitation with Schizophrenia, Bipolar Disorder

The design of and an opinion on the included studies are provided in an H.C. Wainwright & Co. report. In a Dec. 30 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that BioXcel Therapeutics Inc. (BTAI:NASDAQ) launched its pivotal trial program for...
Streetwise Reports | January 6, 2020 |

Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability'

Atara Biotherapeutics' clinical trial design and results are reviewed in a ROTH Capital Partners report. In a May 26 research note, ROTH Capital Partners analyst Tony Butler purported that Atara Biotherapeutics Inc.'s (ATRA:NASDAQ) "updated data from the Phase 1 ...
Streetwise Reports | May 28, 2020 |

Where Did Gold Come From: Black Holes, Aztecs And The Gods

Forever synonymous with wealth, gold has been the most coveted mineral on earth since its first recorded use back in 3000 BC. From Ancient Egypt to the U.S. Treasury its history is one of war, death, love and prosperity. But how did this most precious of precious metal...
Joao Peixe | October 4, 2019 |

The Metal Trump Wants More Than Gold

China has a monopoly on one of the most strategic metals on the planet, and Washington is anxious to change that. Global dominance at this point in the game means control of the rare earths elements that form the backbone of existing technology and the future of technology...
Charles Kennedy | February 14, 2020 |

Assembly Biosciences Stock Sizzles Following Phase 2a Announcement and Buy Rating from Mizuho

Good news is piling up for this healthcare stock engaged in the treatment of hepatitis B as it trades at 5X its average volume with a 30% stock price gain over previous close. Assembly Biosciences Inc (ASMB:NASDAQ) announced in a press release on October 16, 2019, ...
Streetwise Reports | October 17, 2019 |

17 best payday loans online: Quick cash and fast approval this Christmas

If you face a financial emergency, traditional loans may not be a viable option if you have bad credit. So what can you do when you need quick cash – especially close if you need cash for Christmas gifts during the festive season? The best online payday loans are an a...
Dominic Castleberry | December 11, 2023 |

U.S. Energy Firm's Stock at 'Good Entry Point,' Rating Upgraded to Outperform

An update on this company's valuation is provided in a Raymond James report. In an Aug. 13 research note, analyst Pavel Molchanov reported that Raymond James boosted its rating on Chart Industries Inc. (GTLS:NASDAQ) to Outperform from Market Perform, "...
Streetwise Reports | August 20, 2019 |

Correction in Digital Marketing Sector Valuations Creates an Attractive Entry Point for Long-term In

(Click to read report.) Research Capital Corp. is – Initiating Coverage with a BUY Rating and Target Price of $2.20 (USD) on Logiq Inc. ( NEO: LGIQ , OTCQX: LGIQ , Forum ) Logiq’s Presence in Two Large and Growing Segments of Digital Marketing ...
Featured Submission | March 31, 2022 |

Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data

Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher today after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. This morning clinical-stag...
Streetwise Reports | November 19, 2019 |
1 2 3 4 5 6 7 8 9 10 ...